/
Bonk, Inc. (NASDAQ: BNKK) was formerly known as Safety Shot, Inc., and prior to that, Jupiter Wellness, Inc. In August 2023 Jupiter Wellness, Inc. acquired certain assets of GBB Drink Lab Inc which included the blood alcohol reduction drink Sure Shot (the Sure Shot Dietary Supplement ), an over-the-counter drink that can lower blood alcohol content to allow recovery from the effects of alcohol …
$1.21
$0.04 (-3.20%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-1629.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 201.6% YoY with margins expanding 4375.8pp.
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3M
▲ +201.6% YoY
Net Income (TTM)
-$65M
▼ -38.0% YoY
Op. Margin
-969.36%
▲ +4375.8pp YoY
ROIC
-51.23%
▲ +505.3pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$25M
▼ -39.1% YoY
Op. Cash Flow (FY)
-$25M
▼ -39.7% YoY
Net Debt
-$509K
Net Cash Position
Cash & Equiv.
$784K
5Y CAGR: +14.7%
Continue Research
Bonk (BNKK)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bonk scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Bonk scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -969.4% operating margin and a -51.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BNKK's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.